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ABSTRACT
Schwyn, U., Crompton, N.E.A., Blattmann, H., Hauser, B., Klink, B., Parvis, A., Ruslander, D. and
Kaser-Hotz, B., 1998. Potential tumour doubling time: determination of Tpot for various canine and feline
tumours.Veterinary Research Communications, 22(4), 233^247
Spontaneous tumours in dogs and cats are an excellent model for clinical human research, such as in
developing proton conformation radiotherapy for humans. The kinetics of tumour cells can be used
e¡ectively to predict prognosis and response to therapy in patients with tumours. Knowledge of the
kinetic parameters in these tumours is therefore important. In the present study the kinetic parameters
evaluated included the labelling index (LI), relative movement (RM), mitotic index (MI), and potential
doubling time (Tpot). These parameters were determined using in vivo labelling with bromodeoxyur-
idine, £ow cytometry and histological preparation. Samples were obtained and evaluated from 72 dogs
and 20 cats, presenting as patients in our clinic. Within the groups of epithelial and mesenchymal
tumours from dogs and cats, the kinetic parameters LI, RM and MI were compared with Tpot.
Signi¢cant correlations were observed for the comparison Tpot and LI. No correlation was found
between Tpot and RM.
Keywords: bromodeoxyuridine, cat, dog, kinetics, potential doubling time, tumour
Abbreviations: BrdU, bromodeoxyuridine; HBSS, Hank's balanced salt solution; LI, labelling index;
MI, mitotic index; RM, relative movement; Tpot, potential doubling time; TS, duration of S phase
INTRODUCTION
Tumours have been described in small-animal medicine for many years and an increase
in cancer cases has been observed over the past few years. They form an excellent
model for clinical human tumours (Gillette, 1982). The WHO has provided staging
criteria for a variety of animal tumours (Owen, 1980), and surgery, radiotherapy and
chemotherapy are established cancer therapies in veterinary medicine today. Various
imaging techniques, clinical work-up, histopathology and cytology are used during
diagnosis, but it is di¤cult to assess the kinetic potential of a growing tumour at a
particular time. Remvikos and colleagues (1991) described the importance of cell
kinetics as a predictor in clinical tumour diagnostics. Knowing more precisely the
speed at which a tumour mass is growing greatly enhances prognosis, and tumour
therapy can be chosen on a more appropriate and individual patient basis. Potential
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tumour doubling time (Tpot) is the theoretical time predicted for a tumour to double in
cell number. Tpot is an important predictor in radiotherapy because, during standard
treatments intended to kill the tumour cells, any radiotherapeutic procedure may be
overridden by rapid growth of the surviving cells in those tumours with a short
potential doubling time. This may also be true for some chemotherapeutic agents
(Dewhirst et al., 1995). In the method described in this paper, tumour cells are labelled
in vivo and the Tpot of the tumour is determined from a single biopsy a few hours later.
Gratzner (1982) and Dolbeare and colleagues (1983) described a novel method of
cell analysis utilizing a monoclonal antibody to bromodeoxyuridine (BrdU), which
makes it possible to determine accurately the fraction of cells from a given population
in a speci¢ed cell-cycle phase. BrdU is an analogue of uridine and is incorporated
speci¢cally into DNA in place of thymidine. Only those cells which are synthesizing
DNA incorporate BrdU into their DNA, i.e. those cells in the S-phase of the cell cycle.
The use of BrdU overcomes problems associated with injecting patients with radio-
active substances and taking multiple samples. Begg and colleagues (1985) described a
method for estimating the labelling index and the duration of the S-phase from
measurements on a single tumour biopsy. These workers used £ow cytometry to
determine the fraction of cells from a given population in various phases of the cell
cycle. Tpot can be calculated from a single sample of cells taken several hours after
labelling with BrdU in vivo. When tumour cell kinetics are studied using this method,
tumour proliferation rates can be monitored in vivo with a single injection of nontoxic
and nonradioactive bromodeoxyuridine, requiring excision of only a single biopsy 4^8
h later, as shown by Begg (1989).
Numerous reports have been published of analyses of human tumours using this
method (Mitchell et al., 1983; Kinsella et al., 1984; Dressler et al., 1987; Wilson et al.,
1988a,b; Giordano et al., 1991; Rew et al., 1991, 1992; Shimomatsuya et al., 1991;
Popert et al., 1993; Remvikos et al., 1991; Cooke et al., 1994), but little documentation
about the various animal tumours is available. Carter and colleagues (1993) showed
that the use of £ow cytometry is as relevant in veterinary medicine as it is for human
medicine. Flow cytometric analysis of BrdU-labelled cells has led to the description of
various methods of determining Tpot from single veterinary samples. Vail (1993)
examined lymphomas in dogs and discussed the potential bene¢t to the clinical
oncologist of having quantitative kinetic assays for accurate prediction of the response
to treatment and long-term survival. La Rue and colleagues (1994) obtained multiple
samples from 30 dogs with osteosarcomas. Their study investigated the variation
between tumours from di¡erent dogs and compared this with the variation between
di¡erent samples from the same tumour for a number of kinetic parameters. The
results of their study showed that there was more variation between tumours than
within tumours for the kinetic growth parameters examined, such as Tpot.
The major goals of this report are to described the preparation of biopsies from
di¡erent tumour types, to describe a simple, reliable protocol for producing single-cell
suspensions, and to report on the spectrum of growth parameter values observed from
a variety of canine and feline tumours. To our knowledge, only canine lymphomas and
osteosarcomas have been studied to date, and no information is available on tumours
from cats. The results of this predictive assay should be useful for cancer prognosis,
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planning of therapy, and the incorporation of these measurements into clinical trials.
Therefore, it is important to obtain good, reproducible results. Tpot values of various
tumours from dogs and cats were compared with the labelling index (the fraction of
cells which were synthesizing DNA at the time of BrdU administration), the relative
movement (a measure of how far labelled cells progress through S-phase between
BrdU labelling and biopsy excision), and the mitotic index (the fraction of cells
observed to be in mitosis), all from the same tumours.
MATERIALS ANDMETHODS
The study involved an investigation of various tumours from 72 dogs and 20 cats, of
both sexes, and of di¡erent breeds. The median age of the dogs was 9.5 years (range
0.7^16 years) and the median age of the cats was 13 years (range 1^16 years). The
animals were presented to the Small Animal Clinic of the University of Zurich between
January 1995 and May 1996. Owners were informed about the study and asked to
monitor the animals for any subsequent side-e¡ects. Patients mostly presented with a
palpable mass at di¡erent body locations. Clinical diagnosis of neoplasia was based on
histopathological examination. All tumour samples were examined microscopically at
the Institute of Veterinary Pathology of the University of Zurich. The histological type
of the tumour, its grade and mitotic index were determined. The mitotic index was
determined using a standard method by counting the number of mitoses visible in
several microscope ¢elds of 0.17 mm2 (magni¢cation 400-fold). Samples of normal or
in£ammatory tissue were excluded from this analysis.
BrdU (5-bromo-2'-deoxyuridine), an analogue of thymidine, is incorporated into the
DNA during the S-phase of the cell cycle (Cooke et al., 1994). BrdU is not radioactive,
nor is it toxic in the dose required for labelling the cells (Wilson et al., 1988a; Giordano
et al., 1991; Cooke et al., 1994). Infusions of twice the dose of BrdU can be tolerated for
several weeks without myelosuppression (Mitchell et al., 1983; Kinsella et al., 1984).
The BrdU used for intravenous injection in this study was prepared at the Paul
Scherrer Institute, Villigen, Switzerland. BrdU (7.00336 mg/ml: Fluka Chemie AG,
Buchs, Switzerland) was dissolved in pyrogen-free 0.9% NaCl, pH 6, and 51 mmol
NaOH/L. BrdU solutions were tested for stability and sterility. After 6 months the
stability of 500 mg BrdU dissolved in 72 ml sterile, pyrogen-free saline was still greater
than 99%. The sterility test con¢rmed its suitability for use in veterinary medicine. All
the dogs were given 500 mg BrdU and all the cats were given 100 mg BrdU, in single
intravenous injections (Wilson et al., 1988a; La Rue et al., 1994). After an average post-
injection incubation period of 5.78+1.87 h, biopsies were obtained by excising the
tumour. Half the biopsy was ¢xed in 50% ethanol and left overnight in a refrigerator.
The other half was ¢xed in formalin for histological identi¢cation. Excess bromodeox-
yuridine in the circulation is eliminated in a two-step process: ¢rst, BrdU is degraded
to bromouracil, in a manner analogous to the degradation of thymidine; secondly,
enzymatic dehalogenation takes place in the liver to form atomic bromine (Hughes et
al., 1964). The concentration of BrdU in the circulation falls to 30% of its original value
after 24 h.
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A single-cell suspension for £ow cytometric evaluation was obtained from the
biopsy which had been ¢xed in 50% ethanol at 48C. First, the tumour sample was
¢nely minced using two scalpels. During mincing, the tumour was submerged in
approximately 1 ml of pepsin-HCl solution (0.4 mg pepsin (E. Merck, Darmstadt,
Germany) per ml of 0.1 mol/LHCl; Schutte et al., 1987;Wilson et al., 1988a). Next, the
minced tumour was transferred to a conical tube for digestion in 4 ml pepsin-HCl
solution. HCl treatment promotes denaturation of DNA, and simultaneous treatment
with pepsin decreases the subsequent amounts of debris and enhances the staining of
nuclei (van Erp et al., 1988). The tumour suspension was digested for 25 min at 378C in
a water bath, the tube occasionally being manually agitated. Incubation for more than
30 min causes overdigestion of the probe, unsatisfactory DNA pro¢les, and inaccurate
determination of Tpot (Popert et al., 1993). Afterwards, the supernatant was withdrawn
with a syringe and ¢ltered through a 40 mm mesh. The single-cell suspension so
obtained was centrifuged (400g, 5 min), the supernatant was aspirated, and the pellet
was resuspended in 3 ml Hanks' balanced salt solution (HBSS: Life Technologies,
Basel, Switzerland). This suspension was also centrifuged (300g, 5 min), the super-
natant was aspirated, and the pellet was resuspended in 500 ml 2 mol/L HCl, and
incubated for 10 min at 378C in a water bath, after which 3 ml HBSS was added. After
further centrifugation (300g, 5 min), the supernatant was aspirated, and the pellet was
resuspended in 3 ml HBSS. This wash step was repeated. After the next centrifugation
(300g, 5 min), the supernatant was aspirated, and the pellet was resuspended in 3 ml
HBSS with 0.5% Tween 20 (Serva Feinbiochemica, Heidelberg, Germany) and 0.5%
bovine serum albumin (Readysysteme AG, Zurich, Switzerland). After another
centrifugation (300g, 5 min), the supernatant was aspirated, and the pellet was again
resuspended in 3 ml HBSS (White et al., 1990). The cell density in this suspension was
assessed using an electronic counter (Coulter counter). The suspension was centrifuged
once more (300g, 5 min), the supernatant was aspirated, and the pellet was
resuspended in 100 ml HBSS and 20 ml of anti-BrdU FITC-antibody (anti-BrdU-FITC
with gelatine and 0.1% acid; Becton Dickinson, Basel, Switzerland). The cells were
then incubated at room temperature for 25 min, the tube being occasionally manually
agitated. Thereafter 3 ml of HBSS was added and the suspension was centrifuged
(300g, 5 min), the supernatant was aspirated, and the pellet was resuspended in 1 ml
HBSS and 20 ml propidium iodide (1 mg/ml). Propidium iodide is an intercalating dye
which binds to double-stranded DNA (van Erp et al., 1988). The pellet was mixed
thoroughly and cells were left to stain for 5 min at 48C, ready for £ow cytometric
analysis.
In the analysis, 20 000 cells were examined in a FACScan £ow cytometer (Becton
Dickinson, San Jose, CA, USA). Procedures for £ow cytometry have been described in
detail previously (Begg et al., 1985; Wilson et al., 1985; Becton Dickinson, 1989).
Brie£y, four parameters were measured using an argon laser emitting light of 488 nm
wavelength: forward-angle light scatter (cell volume), 908 side-angle light scatter (cell
granularity), green £uorescence (BrdU content) and red £uorescence (DNA content).
The cells were ¢rst identi¢ed on the basis of their size and granularity. Subsequently,
bivariate density `dot-plots' of DNA-area (the area of the DNA £uorescence signal)
versus DNA-width (the width of the DNA £uorescence signal) permitted exclusion by
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gating of abnormal signals and signals from unavoidable cell aggregates. A DNA-area
histogram, and a DNA-area versus BrdU-incorporation bivariate density dot-plot were
prepared from the data for the gated cells (see Figures 1 and 2).
Figure 1. Flow cytometric DNA histogram of canine mammary carcinoma. The cell cycle
phases are labelled: G1, gap 1 phase; S, DNA synthesis phase; G2, gap 2 phase. The units of
DNA content are relative based on £uorescence signal size
Figure 2. Bivariate density dot-plot of cellular DNA content versus bromodeoxyuridine (BrdU)
labelling of a canine mammacarcinoma (see Figure 1). R1, G1-phase cells; R2, G2-phase cells;
R3, labelled cells which have undergone cell division; R4, labelled cells which have not yet
undergone cell division. The units of DNA content and BrdU content are relative based on
£uorescence signal size
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The Tpot method involves calculations using £ow cytometric data of BrdU
incorporation (determined from the green £uorescence of the FITC-labelled anti-
bodies) and total DNA content (determined from the red £uorescence of propidium
iodide incorporated into the DNA) of the tumour cells. Four parameters must be
measured: FG1, FG2, FL and LI. FG1 is the average DNA £uorescence of cells in G1-
phase, FG2 that of cells in G2-phase, and FL that of cells which were BrdU-labelled but
had not yet passed through mitosis (i.e. labelled, non-undivided), while LI is the
fraction of cells labelled with BrdU. To determine FG1 and FG2, G1-phase cells were
identi¢ed from the DNA histogram (Figure 1) and `gated' and their average DNA
content was determined automatically using Lysis II software (Becton Dickinson, San
Jose, CA, USA). FG2 could then be determined as a function of the FG1 value simply
multiplying by 1.9 (VindelÖv and Christensen, 1990). These values were often of
assistance when separating undivided labelled cells from divided labelled cells on the
dot-plots (Figure 2). FL and LI values for calculating Tpot were obtained directly after
`gating'. This optimized analysis permitted a standard procedure to be applied to each
specimen. To determine the average DNA £uorescence of labelled, undivided cells, the
bivariate density dot-plot of DNA-area versus BrdU content was analysed. A gate was
set around the labelled cells in order to determine labelling index. A gate was also set
around the labelled cells which had not yet divided and had not yet entered the G1-
phase of the cell cycle. In the automated statistical subroutine of the Lysis II software,
the average DNA content of FL cells was automatically determined.
Using these data, relative movement (RM), duration of S-phase (TS), and Tpot were
determined. The methods of Begg and colleagues (1985) and White and colleagues
(1990) were employed. RM was determined using: RM= (FL^FG1)/FG2^FG1). Tpot
was calculated from:Tpot = lTS/LI. The calculation assumes that movement of labelled
cells toward G2 is linear with time. TS can be derived from RM using TS = 0.5t/(RM^
0.5), where t is the time between intravenous administration of the BrdU and excision
of the biopsy (Begg et al., 1985). LI, the labelling index, is the fraction of cells which
were synthesizing DNA at the time of BrdU administration and which therefore
incorporated the label. l is a correction factor which takes into account the nonlinear
distribution of cells through the cell cycle; it can be estimated but not calculated exactly
from data made available from a £ow cytometric histogram (Terry et al., 1991). A
realistic estimate of l is 0.8 and this is generally suitable for use with tumour biopsies
(Steel, 1977; Wilson et al., 1988b).
RESULTS
During these studies, the following observations were made regarding procedures
which contributed to an optimal determination of Tpot. The size of the biopsies had to
be at least 1^2 mm3 in order for us to obtain su¤cient cells for £ow cytometry, because
many cells were lost during the work-up procedure. The size of the biopsy also limited
the speed of ¢xation by ethanol, which must penetrate into the centre of the sample, so
the sample size should not be too large. Alanen and colleagues (1989) compared four
standard ¢xation techniques for £ow cytometric determination of Tpot: fresh, formalin-
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¢xed, ethanol-preserved and para¤n-embedded samples. Identical DNA indices and
fairly constant S-phase values were obtained from 50% ethanol-preserved samples
stored at 48C for up to 5 months. In the present study, the samples were preserved in
50% ethanol and stored in a refrigerator at 48C for at least 24 h. This method of
preserving the biopsy permitted analysis of the samples even several days after the
biopsies were taken. It was also possible to perform additional analyses at later dates,
as long as su¤cient material was still available. The pepsin-HCl incubation period for
the diced sample, and the use of Hanks' balanced salt solution, were determined in a
series of tests on di¡erent tumour types. During the course of these tests, three wash-
steps were found to be necessary for obtaining suitable pH conditions for anti-BrdU-
antibody binding following the HCl incubation. Both the duration and the temperature
of antibody incubation were studied. Incubation at room temperature for 25 min gave
optimum results.
BrdU was administered to 107 patients and biopsies were obtained. In 92 cases the
Tpot value was measured successfully. In 9 of the 15 cases where no useful data could be
obtained, histological examination revealed no tumour was present. In 2 other cases
the biopsy was taken from a necrotic area of the tumour, and in the remaining 4 cases
the biopsy sample was too small and too few labelled cells were available for analysis in
the £ow cytometer. Therefore, kinetic cell data were obtained from 85% of the samples.
The majority of the biopsies were taken from dogs (73/92), while the rest (19/92) were
taken from cats. These numbers represent approximately the ratio of dogs to cats
presenting as tumour patients at our clinic. The majority of tumours were categorized
as either epithelial or mesenchymal, because of the distinct ontogenetic origins of these
two tumour types. Tumours such as insulinoma, mesothelioma, malpighioma and
ameloblastoma, which were seldom seen, were listed separately. The potential doubling
time (Tpot), labelling index (LI), relative movement (RM), and mitotic index (MI) were
evaluated for all 92 tumours. Tables I and II show the histopathological classi¢cation
and the kinetic values of the epithelial and mesenchymal tumours in the dogs and cats,
respectively. In these tables, the median values and range are indicated for each
category. Comparisons can be made both between and within the epithelial and
mesenchymal tumour groupings from dogs and cats of Tpot, LI, and RM. Values of
MI are displayed in Table III.
Regression analyses of loge (LI) versus loge (Tpot) for canine and feline mesenchymal
and epithelial tumours are presented in Figures 3A to 3D. Figure 3A presents the
regression line for loge (LI) versus loge (Tpot) of canine mesenchymal tumours. The
same relationship for canine epithelial tumours is presented in Figure 3B. In Figure 3C,
the regression curve of loge (LI) versus loge (Tpot) for feline mesenchymal tumours is
shown, while in Figure 3D the same relationship is presented for feline epithelial
tumours. In all four ¢gures there is a signi¢cant slope and their data lie close to the
regression curve. Figures 4A and 4B display the combined canine and feline
mesenchymal and epithelial Tpot values in linear and logarithmic plots. Figure 4C
presents the distribution of LI values, and Figure 4D the distribution of RM values.
Whereas the RM values were normally distributed, both the Tpot and LI were log-
normally distributed. The regression curve of RM versus loge (Tpot) for all canine and
feline mesenchymal and epithelial tumours is shown in Figure 5A. The correlation
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coe¤cient was close to zero and was not signi¢cant (p=0.25). Figure 5B presents loge
(LI) versus loge (Tpot) for the combined canine and feline mesenchymal and epithelial
tumours. Figure 5C presents the regression curve of loge (MI) versus loge (Tpot) for the
combined canine and feline mesenchymal and epithelial tumours. The modest
correlation was highly signi¢cant (p50.0001). Figure 5D presents the regression curve
of loge (MI) versus loge (LI) for combined canine and feline mesenchymal and
epithelial tumours. The modest correlation was also highly signi¢cant (p50.0001).
TABLE I
Tumour kinetic parameters of all canine tumours studied
Median Median Median
potential labelling relative
Tumour Tumour doubling time index in % movement
class No. type in days (range) (range) (range)
Epithelial tumours 25 See text 9.5 (2.8^63.0) 2.6 (0.4^9.8) 0.87 (0.75^1.06)
Mesenchymal tumours 30 See text 19.3 (2.6^139.4) 2.4 (0.2^10.3) 0.88 (0.59^1.02)
Miscellaneous tumours 7 Mixed 15.6 (5.3^72.9) 1.4 (0.3^3.5) 0.86 (0.81^0.90)
mammary
cancer
Pigment cell tumours 4 Melanoma 14.9 (3.0^76.1) 2.8 (0.5^7.6) 0.91 (0.79^0.94)
Di¡erent tumours 4 Epulides 8.7 (8.5^10.1) 3.0 (2.7^3.5) 0.85 (0.78^0.85)
1 Insulinoma 14.4 3.1 0.77
1 Mesothelioma 4.2 5.4 0.95
1 Malpighioma 8.1 2.3 0.96
TABLE II
Tumour kinetic parameters of all feline tumours studied
Median Median Median
potential labelling relative
Tumour Tumour doubling time index in % movement
class No. type in days (range) (range) (range)
Epithelial tumours 6 See text 5.0 (1.9^10.5) 3.9 (1.5^8.0) 0.91 (0.82^0.96)
Mesenchymal tumours 12 See text 5.9 (1.5^64.6) 3.7 (0.8^14.9) 0.87 (0.69^0.95)
Di¡erent tumours 1 Ameloblastoma 19.7 1.1 0.69
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TABLE III
Histological class, histological type, number of tumours and mitotic index of tumours in dogs
and cats
Median mitotic
Tumour class Tumour type No. index (range)
Canine epithelial Anal sac adenocarcinoma 6 22.5 (11^72)
tumours Breast carinoma 4 27.5 (3^51)
Squamous cell carcinoma 3 39 (9^58)
Sweat gland carcinoma 3 6 (2^37)
Adenocarcinoma of the lung 2 35.5 (17^54)
Carcinoma of the pancreatic duct 1 44
Adenocarcinoma of the cystic duct 1 20
Hepatocellular carcinoma 1 0
Signet-ring cell carcinoma 1 5
Sebaceous adenoma 1 2
Perianal adenoma 1 0
Trichoblastoma 1 5
Canine mesenchymal Mast cell tumour 11 0 (0^11)
tumours Fibrosarcoma 6 5.5 (0^119)
Haemangiosarcoma 5 25 (5^69)
Lymphosarcoma 3 41 (34^60)
Lipoma 2 0 (0^0)
Spindle cell sarcoma 2 59 (48^64)
Haemangiopericytoma 1 55
Di¡erent canine Mixed mammary cancer 7 5 (0^11)
tumours Melanoma 4 3.5 (0^94)
Epulis 4 6.5 (0^11)
Insulinoma 1 6
Mesothelioma 1 32
Malpighioma 1 59
Feline epithelial Squamous cell carcinoma 5 36 (10^107)
tumours Mammary cancer 1 62
Feline mesenchymal Fibrosarcoma 9 25 (0^76)
tumours Spindle cell sarcoma 1 84
Haemangioma 1 0
Intestinal mast cell tumour 1 49
Di¡erent feline tumour Ameloblastoma 1 0
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DISCUSSION
Tumour-volume doubling time is an important clinical parameter but, unlike Tpot, it
cannot be determined rapidly. Tpot is determined from the viable cells in a population;
both quiescent and cycling cells. Tpot is more informative than tumour-cell cycle-time
because it also takes into account the growth fraction, which is the proportion of cells
that are actively dividing. However, at least three sources of potential di¡erence
between Tpot and tumour-volume doubling time exist. First, the contribution of cell
loss through metastasis, exfoliation, cell death, etc., is not quanti¢ed by the Tpot
method (Terry et al., 1992). This can result in inappropriate Tpot values, especially for
carcinomas, where cell loss contributes considerably to the tumour volume kinetics
(Denekamp, 1970). Second, becauseTpot measurements are based on the average of all
Figure 3. Regression analyses of loge labelling index [log LI] versus loge potential doubling time
[loge (Tpot/days)] for various small animal tumours. A, canine mesenchymal tumours; B,
canine epithelial tumours; C, feline mesenchymal tumours; D, feline epithelial tumours.
Labelling index is absolute, not a percentage. The formula for the regression curves and
Pearson's correlation coe¤cients are given below the plots
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cells, this can be misleading when determined from tumours populated by only a small
fraction of the tumour cells (clonogenic stem-cells). Third, heterogeneity in cell growth
across the total tumour mass may contribute to biased Tpot values. Nevertheless, the
potential doubling time expressed in days is an attractive prognostic parameter for the
clinician. Furthermore, numerous authors have reported that there is less intratumour
than intertumour variation, con¢rming that observed di¡erences between Tpot values
re£ect actual di¡erences in growth rate (Wilson et al., 1988b; Giordano et al., 1991;
LaRue et al., 1994).Tpot values have also been reported to be higher in metastases than
in primary tumours (Holmgren et al., 1995).
In the present study, all tumour types displayed a wide range of Tpot values, as
previously reported by Fowler (1986). This emphasizes the need to determine the
tumour kinetic parameters for each patient; no single tumour-characteristic value can
be assumed. The Tpot values were log-normally distributed (see Figures 5A and 5B).
This was also true of the LI and MI values. The tumours in the slow-growing `tails' of
Figure 4. Histogram plots of various kinetic parameters from combined canine and feline
mesenchymal and epithelial tumours. A, potential doubling time [Tpot/days]; B, loge potential
doubling time [loge (Tpot/days)]; C, labelling index [LI]; D, relative movement [RM]. Labelling
index is absolute, not a percentage. Relative movement is a dimensionless quantity. The
continuous black line denotes the best ¢t of the data to a normal distribution
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these distributions tend to represent the more radiotherapy-resistant tumours. Three
experimental parameters contribute to Tpot: t, RM and LI. The average t value was
5.78+1.87 h and was independent of tumour growth kinetics. The average RM was
0.85+0.1, ranging from 0.59 to 1.06.Tpot is inversely proportional to `RM^ 0.5', which
varied from 0.086 to 0.56, a 6.5-fold range. Compared to the range of LI values, the
contribution of RM was negligible and no signi¢cant correlation with Tpot was
observed (see Figure 5A). LI displayed a 75-fold range from 0.2% to 14.9% (average
of combined data 3.5+2.9%). The LI data were clearly skewed to small values: m3/
Figure 5. Regression analyses of various kinetic parameters from combined mesenchymal and
epithelial tumours. A, relative movement [RM] versus loge potential doubling time [loge (Tpot/
days)]; B, loge labelling index [loge LI] versus loge potential doubling time [loge (Tpot/days)]; C,
loge mitotic index [loge (MI/%)] versus loge potential doubling time [loge (Tpot/days)]; D, loge
mitotic index [loge (MI/%)] versus loge labelling index [loge LI]. Labelling index is absolute, not
a percentage. Relative movement is a dimensionless quantity. The formula for the regression
curves and Pearson's correlation coe¤cients are given below the plots
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s=1.4 (see Figure 4C) and were log-normally distributed. The loge(LI) versus loge
(Tpot) regression plots for canine mesenchymal and epithelial tumours both displayed a
distinct slope, with little scatter, indicating a high correlation (see Figures 3A and 3B).
The same was true for feline mesenchymal and epithelial tumours (see Figures 3C and
3D). As LI is inversely proportional to Tpot, and because LI displayed a wide range of
values, it was both expected and observed to be a strong predictor of Tpot (see Figure
5B). If Tpot is derived from LI data alone (Tpot = 0.2365/LI), the estimates of Tpot
deviate from the experimental values by an average of only 28%.
The duration of the S-phase (TS) was determined using t and RM values. The
average TS could also be derived from the slope of the loge (LI) versus loge (Tpot)
regression curves, because the numerical value of the slope equals lTS, and l was ¢xed
at 0.8 (Begg et al., 1985). For canine mesenchymal tumours, TS was 10.0 h; for canine
epithelial tumours, 8.1 h; for feline mesenchymal tumours, 8.5 h; and for feline
epithelial tumours, 5.4 h. This con¢rmed clinical observations indicating that epithelial
tumours tend to grow more quickly than mesenchymal tumours. The TS data also
suggest that the S-phase in feline tumour cells is shorter than it is in canine tumour
cells. Histological determination of MI and Tpot analysis were performed on the same
biopsy sample by dividing the excised material into two small pieces. A modest but
highly signi¢cant correlation between loge (MI) and loge (Tpot) and between loge (MI)
and loge (LI) was observed (see Figures 5C and 5D). Signi¢cant correlations between
these di¡erent tumour growth parameters were expected.
The method described in this study for evaluating tumour kinetic data using BrdU-
labelled tumour cells is straightforward and reproducible. Tpot values were found to
correlate well with the labelling index. In the future it may not be necessary to calculate
Tpot using this method if adequate estimates based on labelling index can be made. It
may even be possible to estimate labelling index noninvasively. This study demon-
strated signi¢cant intertumour variation in the potential doubling time and re-
emphasized the need for analysis of the data from individual patients. Determination
of the kinetic growth of a tumour a¡ords an additional prognostic step towards
improved, patient-speci¢c cancer therapy.
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